| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/02/1998 | WO1998013475A1 Methods for culturing cells |
| 04/02/1998 | WO1998013379A1 METHOD OF CELL INHIBITION USING POLYPEPTIDES DERIVED FROM THE VENOM OF THE AUSTRIALIAN JUMPER ANT $i(MYRMECIA PILOSULA) |
| 04/02/1998 | WO1998013369A1 Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists |
| 04/02/1998 | WO1998013366A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 04/02/1998 | WO1998013357A1 Benzo[1,4]thiazine derivatives and drugs comprising the same |
| 04/02/1998 | WO1998013354A1 Quinazoline derivatives and pharmaceutical compositions containing them |
| 04/02/1998 | WO1998013347A1 Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity |
| 04/02/1998 | WO1998013046A1 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| 04/02/1998 | WO1998013044A1 Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors |
| 04/02/1998 | WO1998013007A2 Methods and compositions for lipidization of hydrophilic molecules |
| 04/02/1998 | WO1998012910A2 NOVEL CREBa ISOFORM |
| 04/02/1998 | CA2267332A1 Methods for culturing cells |
| 04/02/1998 | CA2267179A1 Methods and compositions for lipidization of hydrophilic molecules |
| 04/02/1998 | CA2266336A1 Method of cell inhibition using polypeptides derived from the venom of the austrialian jumper ant myrmecia pilosula |
| 04/02/1998 | CA2265996A1 Aryl-substituted acrylamides with leukotriene b4 (ltb-4) receptor antagonist activity |
| 04/02/1998 | CA2265950A1 Spiro-azacyclic derivatives and their use as therapeutic agents |
| 04/02/1998 | CA2264158A1 Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors |
| 04/02/1998 | CA2264043A1 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| 04/02/1998 | CA2263134A1 Cytotoxic peptides |
| 04/02/1998 | CA2236154A1 Novel creba isoform |
| 04/01/1998 | EP0832981A1 DNA sequences to target proteins to the mammary gland for efficient secretion |
| 04/01/1998 | EP0832977A2 Novel sugar kinase |
| 04/01/1998 | EP0832975A2 Histidinol dehydrogenase from Staphylococcus aureus |
| 04/01/1998 | EP0832973A2 GTP-binding protein |
| 04/01/1998 | EP0832898A2 Substituted amino acid derivatives |
| 04/01/1998 | EP0832891A1 Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods |
| 04/01/1998 | EP0832890A1 Benzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods |
| 04/01/1998 | EP0832888A1 Benzothiophene compounds, compositions, and methods |
| 04/01/1998 | EP0832886A1 Flavon derivatives, process for their preparation, and pharmaceutical compositions containing them |
| 04/01/1998 | EP0832883A1 Tetrahydrobenzo(a)fluorene compounds and methods of use |
| 04/01/1998 | EP0832881A2 Benzofluorene compounds, intermediates, compositions, and methods |
| 04/01/1998 | EP0832880A1 Dihydrobenzofluorene compounds, intermediates, compositions, and methods |
| 04/01/1998 | EP0832879A1 Process for preparing intermediates for thrombin inhibitors |
| 04/01/1998 | EP0832652A1 Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition |
| 04/01/1998 | EP0832260A2 RESISTANCE TO VIRUSES AND VIROIDS IN TRANSGENIC PLANT AND ANIMAL HOSTS EXPRESSING dsRNA-BINDING PROTEIN |
| 04/01/1998 | EP0832236A1 Methods for enhancement of protective immune responses |
| 04/01/1998 | EP0832231A2 A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| 04/01/1998 | EP0832227A1 Method for prolonging the expression of a gene of interest using soluble ctla4 molecules |
| 04/01/1998 | EP0832225A1 Chimeric proteins for use in transport of a selected substance into cells |
| 04/01/1998 | EP0832221A1 Bone stimulating factor |
| 04/01/1998 | EP0832217A1 Modified steroid hormones for gene therapy and methods for their use |
| 04/01/1998 | EP0832216A1 Fibroblast growth factor 15 |
| 04/01/1998 | EP0832215A1 Fibroblast growth factor 11 |
| 04/01/1998 | EP0832204A1 Treatment of insulin resistance |
| 04/01/1998 | EP0832198A1 Oxygen activatable formulations for disinfection or sterilization |
| 04/01/1998 | EP0832190A1 Essential oligonucleotides of vertebrate telomerase |
| 04/01/1998 | EP0832128A2 Thrombin receptor homolog |
| 04/01/1998 | EP0832127A2 Synthetic peptides and pharmaceutical compositions comprising them |
| 04/01/1998 | EP0832126A1 G-protein receptor htnad29 |
| 04/01/1998 | EP0832112A1 Monocyte chemotactic protein-4 |
| 04/01/1998 | EP0832099A1 Reversible cysteine protease inhibitors |
| 04/01/1998 | EP0832098A1 Method of producing igf-i and igfbp-3 with correct folding and disulfide bonding |
| 04/01/1998 | EP0832094A2 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds |
| 04/01/1998 | EP0832092A1 Orally active adenosine kinase inhibitors |
| 04/01/1998 | EP0832091A1 C-4' modified adenosine kinase inhibitors |
| 04/01/1998 | EP0832085A1 Phosphinic acid derivatives with metallopeptidase inhibitory activity |
| 04/01/1998 | EP0832082A1 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists |
| 04/01/1998 | EP0832078A1 N-hydroxyureas as antiinflammatory agents |
| 04/01/1998 | EP0832076A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
| 04/01/1998 | EP0832073A1 Quinazolines and pharmaceutical compositions |
| 04/01/1998 | EP0832066A1 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| 04/01/1998 | EP0832064A1 5-aminoalkyl-2-(2-alkoxyphenyl)-pyrrole derivatives having affinity for dopamine d3 receptors and their use in the treatment of psychoses |
| 04/01/1998 | EP0832063A1 Novel vitamin d derivatives with c-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments |
| 04/01/1998 | EP0832061A1 Benzamide derivatives and their use as vasopressin antagonists |
| 04/01/1998 | EP0832057A1 Diaromatic propynyl or dienyl compounds |
| 04/01/1998 | EP0831939A1 Structurally determined metallo-constructs and applications |
| 04/01/1998 | EP0831925A1 The regulation of systemic immune responses utilizing cytokines and antigens |
| 04/01/1998 | EP0831919A1 Method for pharmaceutical delivery |
| 04/01/1998 | EP0831911A2 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| 04/01/1998 | EP0831910A1 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| 04/01/1998 | EP0831903A1 Connective tissue growth factor |
| 04/01/1998 | EP0831902A1 Muscle trophic factor |
| 04/01/1998 | EP0831893A1 Regulation of cytokine synthesis and release |
| 04/01/1998 | EP0831891A1 Oxidant scavengers |
| 04/01/1998 | EP0831889A1 Use of il-13 to induce 15-lipoxygenase |
| 04/01/1998 | EP0831888A1 Methods for increasing hematopoietic cells |
| 04/01/1998 | EP0831886A1 Thrombopoietin compositions |
| 04/01/1998 | EP0831885A1 Methods and uses of connective tissue growth factor as an induction agent |
| 04/01/1998 | EP0831884A1 Methods and compositions for healing and repair of connective tissue attachment |
| 04/01/1998 | EP0831877A1 Metabolic effects of certain glutathione analogs |
| 04/01/1998 | EP0831871A1 Relaxin-like factor and methods and uses thereof |
| 04/01/1998 | EP0831863A1 Method of improving animal health |
| 04/01/1998 | EP0831856A2 Use of hydroxyethyl starch to prevent post surgical adhesion and as an intracavity carrier device |
| 04/01/1998 | EP0831854A1 Oligonucleotides having phosphorothioate linkages of high chiral purity |
| 04/01/1998 | EP0831851A1 Use of pseudopterosins for promoting wound healing |
| 04/01/1998 | EP0831844A1 Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
| 04/01/1998 | EP0831843A1 Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
| 04/01/1998 | EP0831841A1 Means for treating radiation injuries |
| 04/01/1998 | EP0831837A1 Use of squalamine for the manufacture of a medicament for inhibiting nhe |
| 04/01/1998 | EP0831836A1 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| 04/01/1998 | EP0831835A1 Method for treating anorexia |
| 04/01/1998 | EP0831834A1 Use of debromohymenialdisine and related compounds for treating osteoarthritis |
| 04/01/1998 | EP0831831A1 Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties |
| 04/01/1998 | EP0831830A1 Imidazole compounds |
| 04/01/1998 | EP0831826A1 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride |
| 04/01/1998 | EP0831824A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| 04/01/1998 | EP0831806A1 Multidentate metal complexes and methods of making and using thereof |
| 04/01/1998 | EP0831802A1 Treatment of a trabecular meshwork whose cells are subject ot inhibition of cell division with non-steroidal anti-inflammatory drugs |
| 04/01/1998 | EP0831801A1 Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork |
| 04/01/1998 | EP0831799A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders |